To assess whether EUS (Endoscopic Ultrasound) can serve as a valuable diagnostic tool for identifying PDAC at an early stage in individuals who have recently been diagnosed with diabetes.

Purpose: To improve the rates of early detection of pancreatic cancer.

Pancreatic ductal adenocarcinoma (PDAC) is a type of cancer that starts in the pancreas, a gland located in your abdomen. It happens when some cells in the pancreas start growing abnormally and form a cancer.

Inclusion Criteria:

• Age > 50 years
• Patients diagnosed with diabetes based on FBS/ PPBS/ HbA1C
• Presence of atleast 1 FBS parameter measured in the past 6-18 months which was not > 125 mg/dl
• END-PDAC score > 2

Exclusion Criteria:

• Known or newly detected chronic pancreatitis
• Past history of pancreatic cancer
• History of steroid use
• Contraindications for EUS

All the consecutive patients coming to OP will be screened at AIG for the study criterias, those who are meeting them, shall be enrolled after consent. Patients will enrolled for 1 year and followed up for 3 years